The lead program, LNK001, addresses a critical hurdle in oncology by requiring the co-expression of two antigens, CAIX and ENPP3. While CAIX is highly expressed in renal cell tumors, conventional CAR-T therapies often struggle with toxicity in healthy biliary tissue. By utilizing a logic-gating mechanism, Link aims to preserve antitumor efficacy while minimizing damage to healthy cells, with manufacturing handled by the CTMC joint venture.
In section Releases
Link Cell Therapies Launches Clinical Trial and Secures $90M Funding
Link Cell Therapies has initiated human dosing for its logic-gated CAR-T candidate, LNK001, targeting advanced clear cell renal cell carcinoma at MD Anderson Cancer Center. Alongside this clinical milestone, the company expanded its Series A financing to $90 million and appointed a new slate of executive leadership.
To support this clinical expansion and a planned 2027 colorectal cancer trial, the company raised an additional $30 million in Series A funding. This capital injection follows the appointment of Jie D'Elia as CEO, Friedrich Graf Finckenstein as Chief Medical Officer, and the transition of co-founder Brian Slingerland to Executive Chair. D'Elia, previously of SystImmune and Bristol Myers Squibb, brings a track record of managing significant strategic partnerships, while Finckenstein joins from Iovance Biotherapeutics following his work on the approval of the first solid tumor cell therapy.
Comments (0)
No comments yet. Be the first!